A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety
OBJECTIVE To evaluate quetiapine as an adjunct to paroxetine in patients with comorbid depression and anxiety. METHOD Prospective, multicenter, single-blind trial of patients with DSM-IV major depression and associated anxiety, who were randomized to an 8-week treatment with paroxetine alone (n=54)...
Gespeichert in:
| Veröffentlicht in: | International journal of psychiatry in clinical practice 2004-12, Vol.8 (4), p.205-211 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 211 |
|---|---|
| container_issue | 4 |
| container_start_page | 205 |
| container_title | International journal of psychiatry in clinical practice |
| container_volume | 8 |
| creator | Yargic, L. Ilhan Corapcioglu, Aytul Kocabasoglu, Nese Erdogan, Ayten Koroglu, Gulsah Yilmaz, Dilek |
| description | OBJECTIVE
To evaluate quetiapine as an adjunct to paroxetine in patients with comorbid depression and anxiety.
METHOD
Prospective, multicenter, single-blind trial of patients with DSM-IV major depression and associated anxiety, who were randomized to an 8-week treatment with paroxetine alone (n=54) or paroxetine+quetiapine (n=58). Quetiapine was dosed to 200 mg/day and paroxetine to 60 mg/day, as required.
RESULTS
Decrease in HAM-A scores was significantly greater in the combined therapy group than with paroxetine alone at weeks 2, 4, 6 and LOCF (P |
| doi_str_mv | 10.1080/13651500410005720 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_13651500410005720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1536681362</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-8aea4325dac4058042df6c3e72a4cbac0d77636546f11e7d1822a1dbd22d52ac3</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhSNERX_gAdggL1kQajtxEgSbqqKAVIkNrKO59pjryrGD7dCGx-IJmcttkapKXXms883R6Jyqein4W8EHfiqaTgnFeSs456qX_El1JNpe1KIfhqc0k14TIA6r45yvdlDXqWfVoWzfNVy1w1H154zNKeYZdXG_kCUIJk7uNxqWXfjhsd54F8wbNi2-OI2hYGIlOfBMx2mGRBArW2RordOgV0YGLIPFsrJoGRHxBosLyK5d2f5Td0NcCvu5kADzTiOHBPPKXGAG54Q5uxgY5By1g4LmbvnGke_z6sCCz_ji9j2pvl98_Hb-ub78-unL-dllrVvelXoAhLaRygD91cBbaWynG-wltHoDmpu-7yigtrNCYG_EICUIszFSGiVBNyfV670vBUS35jJOLmv0HgLGJY9CNV03UMaSULFHNWWZE9pxTm6CtI6Cj7uqxgdV0c6rW_tlM6H5v3HXDQEf9oALNqYJrmPyZiyw-pgsFaVdHpvH_N_fW98i-LLVkHC8iksKFN0j1_0FUd241w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1536681362</pqid></control><display><type>article</type><title>A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety</title><source>Taylor & Francis:Master (3349 titles)</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Yargic, L. Ilhan ; Corapcioglu, Aytul ; Kocabasoglu, Nese ; Erdogan, Ayten ; Koroglu, Gulsah ; Yilmaz, Dilek</creator><creatorcontrib>Yargic, L. Ilhan ; Corapcioglu, Aytul ; Kocabasoglu, Nese ; Erdogan, Ayten ; Koroglu, Gulsah ; Yilmaz, Dilek</creatorcontrib><description>OBJECTIVE
To evaluate quetiapine as an adjunct to paroxetine in patients with comorbid depression and anxiety.
METHOD
Prospective, multicenter, single-blind trial of patients with DSM-IV major depression and associated anxiety, who were randomized to an 8-week treatment with paroxetine alone (n=54) or paroxetine+quetiapine (n=58). Quetiapine was dosed to 200 mg/day and paroxetine to 60 mg/day, as required.
RESULTS
Decrease in HAM-A scores was significantly greater in the combined therapy group than with paroxetine alone at weeks 2, 4, 6 and LOCF (P<0.008). Decrease in HAM-D scores was significantly greater in the combined therapy group than with paroxetine alone throughout the study period (P<0.008). Regarding adverse events, it was found that increases in anxiety and insomnia were more prevalent in the paroxetine only group, while increased appetite was more prevalent when quetiapine was added (P<0.05).
CONCLUSION
Quetiapine added to paroxetine is well tolerated and may speed up and improve response in patients with comorbid depression and anxiety.</description><identifier>ISSN: 1365-1501</identifier><identifier>EISSN: 1471-1788</identifier><identifier>DOI: 10.1080/13651500410005720</identifier><identifier>PMID: 24930548</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>anxiety ; atypical antipsychotic ; depression ; paroxetine ; quetiapine</subject><ispartof>International journal of psychiatry in clinical practice, 2004-12, Vol.8 (4), p.205-211</ispartof><rights>2004 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-8aea4325dac4058042df6c3e72a4cbac0d77636546f11e7d1822a1dbd22d52ac3</citedby><cites>FETCH-LOGICAL-c406t-8aea4325dac4058042df6c3e72a4cbac0d77636546f11e7d1822a1dbd22d52ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/13651500410005720$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/13651500410005720$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,59620,59726,60409,60515,61194,61229,61375,61410</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24930548$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yargic, L. Ilhan</creatorcontrib><creatorcontrib>Corapcioglu, Aytul</creatorcontrib><creatorcontrib>Kocabasoglu, Nese</creatorcontrib><creatorcontrib>Erdogan, Ayten</creatorcontrib><creatorcontrib>Koroglu, Gulsah</creatorcontrib><creatorcontrib>Yilmaz, Dilek</creatorcontrib><title>A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety</title><title>International journal of psychiatry in clinical practice</title><addtitle>Int J Psychiatry Clin Pract</addtitle><description>OBJECTIVE
To evaluate quetiapine as an adjunct to paroxetine in patients with comorbid depression and anxiety.
METHOD
Prospective, multicenter, single-blind trial of patients with DSM-IV major depression and associated anxiety, who were randomized to an 8-week treatment with paroxetine alone (n=54) or paroxetine+quetiapine (n=58). Quetiapine was dosed to 200 mg/day and paroxetine to 60 mg/day, as required.
RESULTS
Decrease in HAM-A scores was significantly greater in the combined therapy group than with paroxetine alone at weeks 2, 4, 6 and LOCF (P<0.008). Decrease in HAM-D scores was significantly greater in the combined therapy group than with paroxetine alone throughout the study period (P<0.008). Regarding adverse events, it was found that increases in anxiety and insomnia were more prevalent in the paroxetine only group, while increased appetite was more prevalent when quetiapine was added (P<0.05).
CONCLUSION
Quetiapine added to paroxetine is well tolerated and may speed up and improve response in patients with comorbid depression and anxiety.</description><subject>anxiety</subject><subject>atypical antipsychotic</subject><subject>depression</subject><subject>paroxetine</subject><subject>quetiapine</subject><issn>1365-1501</issn><issn>1471-1788</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1TAQhSNERX_gAdggL1kQajtxEgSbqqKAVIkNrKO59pjryrGD7dCGx-IJmcttkapKXXms883R6Jyqein4W8EHfiqaTgnFeSs456qX_El1JNpe1KIfhqc0k14TIA6r45yvdlDXqWfVoWzfNVy1w1H154zNKeYZdXG_kCUIJk7uNxqWXfjhsd54F8wbNi2-OI2hYGIlOfBMx2mGRBArW2RordOgV0YGLIPFsrJoGRHxBosLyK5d2f5Td0NcCvu5kADzTiOHBPPKXGAG54Q5uxgY5By1g4LmbvnGke_z6sCCz_ji9j2pvl98_Hb-ub78-unL-dllrVvelXoAhLaRygD91cBbaWynG-wltHoDmpu-7yigtrNCYG_EICUIszFSGiVBNyfV670vBUS35jJOLmv0HgLGJY9CNV03UMaSULFHNWWZE9pxTm6CtI6Cj7uqxgdV0c6rW_tlM6H5v3HXDQEf9oALNqYJrmPyZiyw-pgsFaVdHpvH_N_fW98i-LLVkHC8iksKFN0j1_0FUd241w</recordid><startdate>20041201</startdate><enddate>20041201</enddate><creator>Yargic, L. Ilhan</creator><creator>Corapcioglu, Aytul</creator><creator>Kocabasoglu, Nese</creator><creator>Erdogan, Ayten</creator><creator>Koroglu, Gulsah</creator><creator>Yilmaz, Dilek</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041201</creationdate><title>A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety</title><author>Yargic, L. Ilhan ; Corapcioglu, Aytul ; Kocabasoglu, Nese ; Erdogan, Ayten ; Koroglu, Gulsah ; Yilmaz, Dilek</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-8aea4325dac4058042df6c3e72a4cbac0d77636546f11e7d1822a1dbd22d52ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>anxiety</topic><topic>atypical antipsychotic</topic><topic>depression</topic><topic>paroxetine</topic><topic>quetiapine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yargic, L. Ilhan</creatorcontrib><creatorcontrib>Corapcioglu, Aytul</creatorcontrib><creatorcontrib>Kocabasoglu, Nese</creatorcontrib><creatorcontrib>Erdogan, Ayten</creatorcontrib><creatorcontrib>Koroglu, Gulsah</creatorcontrib><creatorcontrib>Yilmaz, Dilek</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of psychiatry in clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yargic, L. Ilhan</au><au>Corapcioglu, Aytul</au><au>Kocabasoglu, Nese</au><au>Erdogan, Ayten</au><au>Koroglu, Gulsah</au><au>Yilmaz, Dilek</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety</atitle><jtitle>International journal of psychiatry in clinical practice</jtitle><addtitle>Int J Psychiatry Clin Pract</addtitle><date>2004-12-01</date><risdate>2004</risdate><volume>8</volume><issue>4</issue><spage>205</spage><epage>211</epage><pages>205-211</pages><issn>1365-1501</issn><eissn>1471-1788</eissn><abstract>OBJECTIVE
To evaluate quetiapine as an adjunct to paroxetine in patients with comorbid depression and anxiety.
METHOD
Prospective, multicenter, single-blind trial of patients with DSM-IV major depression and associated anxiety, who were randomized to an 8-week treatment with paroxetine alone (n=54) or paroxetine+quetiapine (n=58). Quetiapine was dosed to 200 mg/day and paroxetine to 60 mg/day, as required.
RESULTS
Decrease in HAM-A scores was significantly greater in the combined therapy group than with paroxetine alone at weeks 2, 4, 6 and LOCF (P<0.008). Decrease in HAM-D scores was significantly greater in the combined therapy group than with paroxetine alone throughout the study period (P<0.008). Regarding adverse events, it was found that increases in anxiety and insomnia were more prevalent in the paroxetine only group, while increased appetite was more prevalent when quetiapine was added (P<0.05).
CONCLUSION
Quetiapine added to paroxetine is well tolerated and may speed up and improve response in patients with comorbid depression and anxiety.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>24930548</pmid><doi>10.1080/13651500410005720</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1365-1501 |
| ispartof | International journal of psychiatry in clinical practice, 2004-12, Vol.8 (4), p.205-211 |
| issn | 1365-1501 1471-1788 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_13651500410005720 |
| source | Taylor & Francis:Master (3349 titles); Taylor & Francis Medical Library - CRKN |
| subjects | anxiety atypical antipsychotic depression paroxetine quetiapine |
| title | A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T13%3A17%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prospective%20randomized%20single-blind,%20multicenter%20trial%20comparing%20the%20efficacy%20and%20safety%20of%20paroxetine%20with%20and%20without%20quetiapine%20therapy%20in%20depression%20associated%20with%20anxiety&rft.jtitle=International%20journal%20of%20psychiatry%20in%20clinical%20practice&rft.au=Yargic,%20L.%20Ilhan&rft.date=2004-12-01&rft.volume=8&rft.issue=4&rft.spage=205&rft.epage=211&rft.pages=205-211&rft.issn=1365-1501&rft.eissn=1471-1788&rft_id=info:doi/10.1080/13651500410005720&rft_dat=%3Cproquest_cross%3E1536681362%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1536681362&rft_id=info:pmid/24930548&rfr_iscdi=true |